Table 1.

Chemical and biological preparations investigated for the management and/or treatment of COVID-19 to date

Classification of chemical and biological preparations	Agents
Glucocorticosteroids	Dexamethasone (Bartoletti et al., 2021)
	Methylprednisolone (Hu et al., 2020)
Antiviral agents	Umifenovir (Khamitov et al., 2008; Kadam and Wilson, 2017)
	Ribavirin (Foolad et al., 2019)
	Lopinavir (Chu et al., 2004)
	Ritonavir (Chu et al., 2004)
	Favipiravir (Mentré et al., 2015)
	Remdesivir (Siegel et al., 2017)
Antimalrarial/Antihelminthic agents	Nitazoxanide (Rossignol, 2016)
	Chloroquine (Savarino et al., 2003; Al-Bari, 2017)
	Hydroxychloroquine (Savarino et al., 2003; Al-Bari, 2017)
	Pyronaridine (Krishna et al., 2021)
	Artesunate (Krishna et al., 2021)
Immunomodulators	Tocilizumab (Xu et al., 2020)
	Baricitinib (Goletti and Cantini, 2021)
	Imatinib (de Wilde et al., 2011; La Rosée et al., 2020; Li and De Clercq, 2020)
	Dasatinib (de Wilde et al., 2011; La Rosée et al., 2020; Li and De Clercq, 2020)
	Cyclosporine (de Wilde et al., 2011; La Rosée et al., 2020; Li and De Clercq, 2020)
	Ruxolitinib (de Wilde et al., 2011; La Rosée et al., 2020; Li and De Clercq, 2020)
Inhibitors for the human transmembrane surface protease, TMPRSS2	Camostat (Hoffmann et al., 2020; Breining et al., 2021)
	Nafamostat (Hoffmann et al., 2020; Breining et al., 2021)